Lessons Learned from the Seladelpar Phase 2b Study

Melissa Palmer, MD
Liver Forum
1/22/21
Disclosures

• CMO Gannex Pharma, a wholly owned subsidiary of Ascletis
Seladelpar

- PPAR-delta agonist
- Nov ‘19 Termination Phase 2 NASH and PSC / Hold Phase 3 PBC
- “Planned, blinded histological assessments of the first tranche of liver biopsies in the trial revealed atypical histological findings, including histology characterized as an interface hepatitis presentation, with or without biliary injury”
- Asymptomatic, improved or stable liver blood tests
- Findings were also unexpected based on pre-clinical and clinical experience
Histology?

- Interface hepatitis
- Piecemeal necrosis
- Process of inflammation and erosion of the hepatic parenchyma leading to a disappearance of the interface between the lobule and portal tracts
- Autoimmunity
- AIH/NASH?
- AIH - DILI?
• DILI with normal or unchanged ATs?
• AI DILI?
• External DILI safety committee
Clinical Development Operational

- Eligibility criteria?
- Baseline biopsy reporting?
- How many pathologists?
- Glass Slide or digital?
- Tranche/real time?
- Scrambling?
- Paired biopsies evaluation versus PBO at EOT?